Verition Fund Management’s Aerie Pharmaceuticals AERI Stock Holding History

Verition Fund Management’s Portfolio AERI Stock Details AERI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-23,275	Closed	-$352K	–	3178
2022 Q3	$352K	Buy	+23,275	New	+$271K	﹤0.01%	2115
2022 Q1	–	Sell	-16,544	Closed	-$116K	–	3196
2021 Q4	$116K	Buy	+16,544	New	+$173K	﹤0.01%	2314

Verition Fund Management's AERI Position: Q4 2022 in Review

Verition Fund Management sold out of Aerie Pharmaceuticals (AERI) in Q4 2022, closing a stake of 23,275 shares — an estimated $352K sold.

Verition Fund Management first reported a position in AERI in Q4 2021 and held it in 2 quarters. The position peaked at $352K in Q3 2022. 0 funds tracked by Wall St. Rank hold AERI as of Q4 2022.

Verition Fund Management reported no remaining Aerie Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
Verition Fund Management sold 23,275 Aerie Pharmaceuticals shares in Q4 2022, an estimated $352K.
Verition Fund Management first reported a position in Aerie Pharmaceuticals in Q4 2021 and held it in 2 quarters.
Verition Fund Management's Aerie Pharmaceuticals position peaked at $352K in Q3 2022.
0 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q4 2022.

Based on Verition Fund Management's 13F filing for Q4 2022, filed 14 Feb 2023.